Low-molecular-weight heparin for prevention of restenosis after femoropopliteal percutaneous transluminal angioplasty: A randomized controlled trial

Journal of Vascular Surgery

Volumn 44, Issue 6, 2006, Pages 1247-1253

  Koppensteiner, Renate ^a   Spring, Silviana ^a   Amann Vesti, Béatrice R ^a   Meier, Thomas ^a   Pfammatter, Thomas ^b   Rousson, Valentin ^c   Banyai, Martin ^a   van der Loo, Bernd ^a  

^a Department of Internal Medicine   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DALTEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

AGED; ARTERY OCCLUSION; ARTICLE; BLEEDING; CLAUDICATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; ECHOGRAPHY; FEMALE; FEMOROPOPLITEAL ARTERY OBSTRUCTION; HUMAN; INJECTION SITE CONTUSION; LIMB ISCHEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PATIENT COMPLIANCE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, BALLOON; ARTERIAL OCCLUSIVE DISEASES; ASPIRIN; DALTEPARIN; DRUG THERAPY, COMBINATION; FEMALE; FEMORAL ARTERY; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INTERMITTENT CLAUDICATION; ISCHEMIA; LOWER EXTREMITY; MALE; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS; POPLITEAL ARTERY; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECURRENCE; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; VASCULAR PATENCY;

EID: 33751502798     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2006.07.044     Document Type: Article

References (22)

1. Johnston K.W., Rae M., Hogg-Johnston S.A., Colapinto R.F., Walker P.M., Baird R.J., et al. Five-year results of a prospective study of percutaneous transluminal angioplasty. Ann Surg 206 (1987) 403-413
2. Berkowitz H.D., Spence R.K., and Freiman D.B. Long-term results of transluminal angioplasty of the femoral arteries. In: Dotter C.T., Grüntzig A.R., Schoop W., et al. (Eds). Percutaneous transluminal angioplasty (1983), Springer Verlag, Berlin 207-214
3. Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ 308 (1994) 159-168
4. Wilensky R.L., March K.L., Gradus-Pizlu I., Sandusky G., Fineberg N., and Hathaway D.R. Vascular injury, repair, and restenosis after percutaneous transluminal angioplasty in the atherosclerotic rabbit. Circulation 92 (1995) 2995-3005
5. Wilson N.V., Salisbury J.R., and Kakkar V.V. Effect of low molecular weight heparin on myointimal hyperplasia. Brit J Surg 78 (1991) 1381-1383
6. Edmondson R.A., Cohen A.T., Das S.K., Wagner M.B., and Kakkar V.V. Low-molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting. Lancet 344 (1994) 914-918
7. Dormandy J.A., and Rutherford R.B. Management of peripheralarterial disease (PAD). Transatlantic InterSociety Consensus (TASC). J Vasc Surg 31 (2000) S1-S296
8. Ranke C., Creutzig A., and Alexander K. Duplex scanning of peripheral arteries: correlation of the peak velocity ratio with angiographic diameter reduction. Ultrasound Med Biol 18 (1992) 433-440
9. Rutherford R.B., Baker J.D., Ernst C., Johnston K.W., Porter J.M., Ahn S., et al. Recommended standards for reporting dealing with lower extremity ischemia: revised version. J Vasc Surg 26 (1997) 517-538
10. Warkentin T., Levine M., Hirsh J., Horsewood P., Roberts R.S., Gent M., et al. Heparin-induced thrombocytopenia in patients treated with low molecular weight heparin. N Engl J Med 332 (1995) 1330-1335
11. Strecker E.P., Göttmann D., Boos I., and Vetter S. Low-molecular-weight heparin (reviparin) reduces the incidence of femoropopliteal in-stent restenosis: preliminary results of an ongoing study. Cardiovasc Intervent Radiol 21 (1998) 375-379
12. Schweizer J., Müller A., Forkmann L., Hellner G., and Kirch W. Potential use of a low-molecular-weight heparin to prevent restenosis in patients with extensive wall damage following peripheral angioplasty. Angiology 52 (2001) 659-669
13. Gimple L.W., Herrmann H.C., Winniford M., and Mammen E. Usefulness of subcutaneous low molecular weight heparin (ardeparin) for reduction of restenosis after percutaneous transluminal angioplasty. Am J Cardiol 83 (1999) 1524-1529
14. Lablanche J.M., McFadden E.P., Meneveau N., Lusson J.R., Bertrand B., Metzger J.P., et al. Effect of nardoparin, a low-molecular-weight heparin, on clinical and angiographic restenosis after coronary balloon angioplasty: the FACT study. Fraxiparine Angioplastie Coronaire Transluminale. Circulation 96 (1997) 3396-3402
15. Karsch K.R., Preisack M.B., Baildon R., Eschenfelder V., Foley D., Garcia E.J., et al. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of restenosis after PTCA, early administration of reviparin in a double-blind unfractionated heparin and placebo-controlled evaluation. J Am Coll Cardiol 28 (1996) 1437-1443
16. Ross R. The pathogenesis of atherosclerosis-an update. N Engl J Med 314 (1986) 488-500
17. Ao P.Y., Hawthorne W.J., Coombs R., and Fletcher J.P. Suppression of intimal hyperplasia with low molecular weight heparin in a sheep model. Int Angiol 18 (1999) 131-139
18. Kereiakes D.J. Adjunctive pharmacotherapy before percutaneous coronary intervention in non ST-elevation acute coronary syndromes: the role of modulating inflammation. Circulation 108 (2003) III22-III27
19. Christopherson K.W., Campbell J.J., Travers J.B., and Hromas R.A. Low-molecular weight heparins inhibit CCL21-induced T cell adhesion and migration. J Pharmacol Exp Ther 302 (2002) 290-295
20. Manduteanu I., Voinea M., Capraru M., Dragomir E., and Simionescu M. A novel attribute of enoxaparin: inhibition of monocyte adhesion to endothelial cells by a mechanism involving cell adhesion molecules. Pharmacology 65 (2002) 32-37
21. Hua H.T., Al-Badawi H., Entabi F., Stoner M.C., Diamond R.E., Bonheur J.A., et al. CXC chemokine expression and synthesis in skeletal muscle durino ischemia/reperfusion. J Vasc Surg 42 (2005) 337-343
22. Barani J., Nilsson J.A., Mattiasson I., Lindblad B., and Gottsater A. Inflammatory mediators are associated with 1-year mortality in critical limb ischemia. J Vasc Surg 42 (2005) 75-80